MeiraGTx (MGTX) announced the Company will exhibit five posters at the European Society of Gene and Cell Therapy, ESGCT, 2024 Annual Congress, ...

MeiraGTx (MGTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) met its primary study objective of safety and tolerability.

The posters are available on the Posters and Publications page of the Company’s website.

MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 ...

Buy MGTX near 5.38 target n/a stop loss @ 5.36. Details The technical summary data tells us to buy MGTX near 5.38, but there is no current upside target from the summary table. In this case we should ...

Option chain shows key data for MeiraGTx Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment ...

The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.